Cortical Neurons In Dementia With Lewy Bodies is a cell type relevant to neurodegenerative disease research. This page covers its role in brain function, involvement in disease processes, and significance for therapeutic strategies.
Dementia with Lewy bodies (DLB) is characterized by widespread cortical involvement with Lewy body pathology affecting multiple brain regions. Cortical neurons, particularly pyramidal cells and interneurons, demonstrate significant degeneration that underlies the cognitive, psychiatric, and motor features of the disease.
- Layer I: Molecular layer (sparse neurons)
- Layer II: External granular (small pyramids)
- Layer III: External pyramidal (pyramidal neurons)
- Layer IV: Internal granular (stellate cells)
- Layer V: Internal pyramidal (large pyramids)
- Layer VI: Multiform layer (polymorphic)
- Excitatory: Glutamatergic
- Apical dendrites: Extend to layer I
- Basal dendrites: Local connections
- Markers: Tuj1, Cux1, Satb2
- Parvalbumin (PV): Fast-spiking
- Somatostatin (SST): Dendrite-targeting
- VIP: Interneuron-specific
- Reelin: Cajal-Retzius
- Frontal cortex: Executive dysfunction
- Temporal cortex: Memory, language
- Parietal cortex: Visuospatial
- Occipital cortex: Visual hallucinations
- Subcortical inputs: Thalamus, basal ganglia
- Cortical connections: Association fibers
- Neuromodulatory: Acetylcholine, 5-HT, NE
¶ Lewy Body Pathology
- Lewy bodies: Intraneuronal inclusions
- Lewy neurites: Axonal pathology
- Brainstem type: Early
- Cortical type: Diffuse
- Temporal lobe: Early involvement
- Frontal cortex: Executive deficits
- Anterior cingulate: Psychiatric symptoms
- Primary sensory: Late
- Aggregation: Fibril formation
- Membrane binding: Membrane permeability
- Organelle dysfunction: Mitochondria, ER
- Synaptic dysfunction: Presynaptic terminals
- Spread: Prion-like propagation
- Severe loss: Up to 70% in cortex
- Basal forebrain: NBM degeneration
- Clinical correlation: Cognitive severity
- Treatment target: AChE inhibitors
- Substantia nigra: Moderate loss
- Motor symptoms: Parkinsonism
- Treatment implications: Levodopa
- Raphe nuclei: Variable involvement
- Depression: Psychiatric features
- Hallucinations: 5-HT2A changes
- Microglial activation: Chronic
- Cytokine elevation: IL-1β, TNF-α
- Astrocytic: Reactive changes
- Peripheral immune: Blood-brain barrier
| Feature |
DLB |
AD |
| Primary protein |
α-Syn |
Tau, Aβ |
| Hippocampus |
Moderate |
Severe |
| Cortical neurons |
Diffuse loss |
Layer-specific |
| Pathology type |
Lewy bodies |
NFTs, plaques |
- Alpha rhythm: Reduced power
- Beta oscillations: Slowed
- Gamma: Impaired coupling
- Cortical slowing: EEG delta/theta
- Pyramidal cells: Reduced firing
- Inhibitory neurons: Disinhibition
- Synaptic plasticity: LTP impairment
- Cortical hyperexcitability: Early
- Cholinesterase inhibitors: Donepezil, rivastigmine
- Memantine: NMDA antagonist
- Limited efficacy: vs. AD
- Antipsychotics: Avoid (severe sensitivity)
- Pimavanserin: 5-HT2A inverse agonist
- Antidepressants: SSRIs, SNRIs
- Levodopa: Modest benefit
- Dopamine agonists: Limited
- Parkinsonism: Variable response
- Cognitive stimulation: Benefit
- Physical exercise: Maintain function
- Sleep hygiene: REM behavior disorder
- Visual management: Reduce hallucinations
- α-Syn aggregation inhibitors: In trials
- Immunotherapy: Active/passive
- Neurotrophic: Support neurons
- Anti-inflammatory: Modulation
- α-Syn transgenic: A53T, A30P
- Viral vectors: AAV-α-syn
- Transgenic: Thy1-α-syn
- DLB models: Combined pathology
- iPSC cortical neurons: Patient-derived
- Neuronal cultures: α-Syn aggregation
- Organoids: Cortical circuits
- Co-cultures: Glia-neuron
- Fluctuating cognition: Variability
- Visual hallucinations: Detailed, formed
- Parkinsonism: Bradykinesia, rigidity
- REM sleep behavior disorder: Loss of atonia
- Low uptake: DaTscan
- Prominent depression
- Delusions
- Sensitivity to antipsychotics
- CSF: α-Synuclein (decreased)
- Imaging: MRI, PET
- Sleep: Polysomnography
- Genetics: GBA, SNCA
The study of Cortical Neurons In Dementia With Lewy Bodies has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology. 2017;89(1):88-100.
- Outeiro TF, Koss DJ, Erskine D, et al. Dementia with Lewy bodies: An update and overview. J Neurol Neurosurg Psychiatry. 2023;94(10):797-808.
- Walker Z, Possin KL, Boeve BF, Aarsland D. Lewy body dementias. Lancet. 2015;386(10004):1683-1697.
- Colloby SJ, Pakrasi S, Firbank MJ, et al. In vivo SPECT imaging of dopaminergic function with I-123-FP-CIT in dementia with Lewy bodies. J Neural Transm. 2020;127(1):75-84.
- Gomperts SN. Lewy Body Dementia. Continuum (Minneap Minn). 2016;22(2 Dementia):435-463.